Edition:
United Kingdom

Pharmaceuticals

Page 1

Boya Bio-Pharmaceutical Group Says It Plans Asset Acquisition, Share Trade To Halt From June 12

Tuesday, 11 Jun 2019

June 11 (Reuters) - Boya Bio-pharmaceutical Group Co Ltd <300294.SZ>::SAYS IT PLANS ASSET ACQUISITION, SHARE TRADE TO HALT FROM JUNE 12.

Co.Don AG: Strategic Expansion And Further Internationalisation

Wednesday, 13 Mar 2019

March 13 (Reuters) - CO.DON AG ::DGAP-NEWS: CO.DON AG: STRATEGIC EXPANSION AND FURTHER INTERNATIONALISATION.IS REVIEWING VARIOUS FINANCING OPTIONS, WHICH INCLUDE POSSIBILITY OF RAISING EQUITY.

Sellas Life Sciences Announces Review Of Strategic Alternatives

Tuesday, 26 Feb 2019

Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES.SELLAS LIFE SCIENCES ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES.SELLAS LIFE SCIENCES GROUP INC - DISCUSSIONS ON DEVELOPMENT PATH FOR NELIPEPIMUT-S (NPS) ONGOING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA).SELLAS LIFE SCIENCES GROUP INC - DISCUSSIONS ON DEVELOPMENT PATH FOR NELIPEPIMUT-S (NPS) ONGOING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA).SELLAS LIFE SCIENCES GROUP INC - ENGAGES CANTOR FITZGERALD & CO. IN ITS REVIEW OF STRATEGIC ALTERNATIVES AS IT SEEKS TO MAXIMIZE SHAREHOLDER VALUE.SELLAS LIFE SCIENCES GROUP INC - PLANS TO EXPLORE A WIDE RANGE OF STRATEGIC ALTERNATIVES THAT INCLUDE, AMONG OTHERS, A SALE OF COMPANY,OTHERS.SELLAS LIFE SCIENCES - DOES NOT EXPECT TO DISCUSS/DISCLOSE DEVELOPMENTS REGARDING STRATEGIC PROCESS UNLESS AND UNTIL ITS BOARD HAS APPROVED ACTION.SELLAS LIFE SCIENCES - STRATEGIC ALTERNATIVES ALSO INCLUDE MERGER/ REVERSE MERGER WITH ANOTHER COMPANY, STRATEGIC INVESTMENT/FINANCING,OTHERS.SELLAS LIFE SCIENCES- PLANNED PHASE 3 PROSPECTIVE STUDY OF GPS MONOTHERAPY IN PATIENTS WITH AML WHO ACHIEVED MORPHOLOGICAL SECOND COMPLETE RESPONSE.SELLAS -ALTERNATIVES ALSO HAS FUNDED COLLABORATION/PARTNERSHIP WOULD ALLOW TO CONTINUE CURRENT BUSINESS PLAN OF ADVANCING DEVELOPMENT OF GPS, NPS.

Vistin Pharma To Close Energy Trading Business Unit Acitvity

Tuesday, 8 Jan 2019

Jan 8 (Reuters) - Vistin Pharma ASA ::REG-VISTIN PHARMA ASA : UPDATE ON ENERGY TRADING BUSINESS.SAYS WILL CONTINUE TO MANAGE OUTSTANDING FINANCIAL DERIVATIVE CONTRACTS, BUT WILL NOT ENTER INTO NEW ENERGY TRADING INVESTMENTS AND CLOSE ENERGY TRADING BUSINESS.TO CLOSE ENERGY TRADING BUSINESS UNIT ACITVITY.CURRENT MARKET CONDITIONS HAVE MADE IT DIFFICULT TO RAISE EXTERNAL CAPITAL FOR CLOSED-END FUNDS.TRADING POSITIONS TAKEN BY COMPANY HAS SO FAR NOT PERFORMED AS PLANNED.WILL NOT ENTER INTO NEW ENERGY TRADING INVESTMENTS AND CLOSE ENERGY TRADING BUSINESS.NO NEW ENERGY TRADING INVESTMENTS WILL BE MADE.

AstraZeneca Appoints José Baselga To Head R&D For Oncology

Monday, 7 Jan 2019

Jan 7 (Reuters) - AstraZeneca PLC ::ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES.JOSÉ BASELGA, MD, PHD, APPOINTED TO HEAD RESEARCH AND DEVELOPMENT FOR ONCOLOGY (ADDS DROPPED WORD 'ONCOLOGY').RESEARCH AND DEVELOPMENT UNITS AND COMMERCIAL UNITS WILL EACH BE REPRESENTED ON SENIOR EXECUTIVE TEAM OF ASTRAZENECA.TO CREATE THERAPY AREA-FOCUSED RESEARCH AND DEVELOPMENT UNITS FOR DISCOVERY THROUGH TO LATE-STAGE DEVELOPMENT FOR BIOPHARMACEUTICALS & ONCOLOGY.TO ALSO CREATE MIRRORED COMMERCIAL UNITS - ONE FOR BIOPHARMACEUTICALS AND ONE FOR ONCOLOGY.

AB Science Completes Reorganization Of Its Clinical Development Activity

Wednesday, 19 Dec 2018

Dec 19 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE PROVIDES AN UPDATE ON THE RESTRUCTURING OF ITS CLINICAL DEVELOPMENT DEPARTMENT IN 2018.HAS COMPLETED REORGANIZATION OF ITS CLINICAL DEVELOPMENT ACTIVITY TO ENSURE COMPLIANCE WITH GOOD CLINICAL PRACTICES.ANSM INSPECTION WAS RECENTLY CONDUCTED TO ENSURE THAT CONDITIONS REQUIRED TO LIFT CLINICAL HOLD HAVE BEEN MET.AB SCIENCE WILL DISCLOSE AGENCY DECISION ONCE AVAILABLE.AT THIS STAGE, AB SCIENCE DOES NOT INTEND TO PROVIDE ANY INFORMATION REGARDING TIMING OF ANSM DECISION.

Aspen On Track To Meet FY Guidance Of Commercial Pharma Organic Revenue Growth

Thursday, 13 Dec 2018

Dec 13 (Reuters) - Aspen Pharmacare Holdings Ltd ::ASPEN PHARMACARE HOLDINGS LTD - ON TRACK TO MEET ITS FULL YEAR GUIDANCE OF COMMERCIAL PHARMA ORGANIC REVENUE GROWTH.ASPEN - FY GUIDANCE OF COMMERCIAL PHARMA ORGANIC REVENUE GROWTH RANGING BETWEEN 1% AND 4% BASED ON PERFORMANCE FOR FIVE MONTHS TO 30 NOVEMBER 2018.ASPEN - MANUFACTURING REVENUE FROM APIS HAS DONE BETTER THAN EXPECTED FOR FIVE MONTHS TO 30 NOVEMBER AND IS IN LINE WITH REVENUE FOR COMPARABLE PERIOD.ASPEN PHARMACARE - POSITIVE PERFORMANCE FROM COMMERCIAL PHARMA IN MOST EMERGING MARKETS, JAPAN OFFSET BY WEAKER PERFORMANCE IN EUROPE & RUSSIA IN FY.ASPEN PHARMACARE- SIGNIFICANT PROGRESS MADE IN PROCURING FULFILMENT OF CONDITIONS PRECEDENT TO DISPOSAL TO B.A.S. S.A. OF ASPEN'S NUTRITIONALS BUSINESS.

Aspen On Track To Meet FY Guidance Of Commercial Pharma Organic Revenue Growth

Thursday, 13 Dec 2018

Dec 13 (Reuters) - Aspen Pharmacare Holdings Ltd ::ASPEN PHARMACARE HOLDINGS LTD - ON TRACK TO MEET ITS FULL YEAR GUIDANCE OF COMMERCIAL PHARMA ORGANIC REVENUE GROWTH.ASPEN - FY GUIDANCE OF COMMERCIAL PHARMA ORGANIC REVENUE GROWTH RANGING BETWEEN 1% AND 4% BASED ON PERFORMANCE FOR FIVE MONTHS TO 30 NOVEMBER 2018.ASPEN - MANUFACTURING REVENUE FROM APIS HAS DONE BETTER THAN EXPECTED FOR FIVE MONTHS TO 30 NOVEMBER AND IS IN LINE WITH REVENUE FOR COMPARABLE PERIOD.ASPEN PHARMACARE - POSITIVE PERFORMANCE FROM COMMERCIAL PHARMA IN MOST EMERGING MARKETS, JAPAN OFFSET BY WEAKER PERFORMANCE IN EUROPE & RUSSIA IN FY.ASPEN PHARMACARE- SIGNIFICANT PROGRESS MADE IN PROCURING FULFILMENT OF CONDITIONS PRECEDENT TO DISPOSAL TO B.A.S. S.A. OF ASPEN'S NUTRITIONALS BUSINESS.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary